79 research outputs found
Therapeutic Management of Hypothenar Hammer Syndrome Causing Ulnar Nerve Entrapment
Introduction. The hypothenar hammer syndrome is a rare traumatic vascular disease of the hand. Method and Materials. We report the case of a 43-years-old man with a painful tumefaction of the left hypothenar region. The ulnar artery appeared thrombosed clinically and radiologically. The patient underwent surgery to resolve the ulnar nerve compression and revascularise the artery. Results. The symptoms disappeared immediately after surgery. The arterial flow was reestablished. Postoperatively on day 20, a new thrombosis of the ulnar artery occurred.
Conclusion. Hypothenar hammer syndrome is caused by repetitive trauma to the heel of the hand. The alterations of the vessel due to its chronic inflammation caused an acute compression of the ulnar nerve at the Guyon's canal and, in our case, do not allow a permanent revascularisation of the ulnar artery
Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment
The FcγRII (CD32) ligands are IgFc fragments and pentraxins. The existence of additional ligands is unknown. We engineered T cells with human chimeric receptors resulting from the fusion between CD32 extracellular portion and transmembrane CD8α linked toCD28/ζ chain intracellular moiety (CD32-CR). Transduced T cells
recognized three breast cancer (BC) and one colon cancer cell line
among 15 tested in the absence of targeting antibodies. Sensitive
BC cell conjugation with CD32-CR T cells induced CD32 polarization
and down-regulation, CD107a release, mutual elimination,
and proinflammatory cytokine production unaffected by human
IgGs but enhanced by cetuximab. CD32-CR T cells protected immunodeficient
mice from subcutaneous growth of MDA-MB-468
BC cells. RNAseq analysis identified a 42 gene fingerprint predicting
BC cell sensitivity and favorable outcomes in advanced BC.
ICAM1 was a major regulator of CD32-CR T cellâmediated cytotoxicity.
CD32-CR T cells may help identify cell surface CD32 ligand(s)
and novel prognostically relevant transcriptomic signatures and
develop innovative BC treatments
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study
Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major candidate genes for monogenic hypercholesterolemia (LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1). Results A total of 213 variants were detected in 1076 subjects. About 90% of them had a pathogenic or likely pathogenic variants. More than 94% of patients carried pathogenic variants in LDLR gene, 27 of which were novel. Pathogenic variants in APOB and PCSK9 were exceedingly rare. We found 4 true homozygotes and 5 putative compound heterozygotes for pathogenic variants in LDLR gene, as well as 5 double heterozygotes for LDLR/APOB pathogenic variants. Two patients were homozygous for pathogenic variants in LDLRAP1 gene resulting in autosomal recessive hypercholesterolemia. One patient was found to be heterozygous for the ApoE variant p.(Leu167del), known to confer an FH phenotype. Conclusions This study shows the molecular characteristics of the FH patients identified in Italy over the last two years. Full phenotypic characterization of these patients and cascade screening of family members is now in progress
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)
BACKGROUND AND AIMS:
Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease. We set up an Italian nationwide network aimed at facilitating the clinical and genetic diagnosis of genetic dyslipidemias named LIPIGEN (LIpid TransPort Disorders Italian GEnetic Network).
METHODS:
Observational, multicenter, retrospective and prospective study involving about 40 Italian clinical centers. Genetic testing of the appropriate candidate genes at one of six molecular diagnostic laboratories serving as nationwide DNA diagnostic centers.
RESULTS AND CONCLUSIONS:
From 2012 to October 2016, available biochemical and clinical information of 3480 subjects with familial hypercholesterolemia identified according to the Dutch Lipid Clinic Network (DLCN) score were included in the database and genetic analysis was performed in 97.8% of subjects, with a mutation detection rate of 92.0% in patients with DLCN score 656. The establishment of the LIPIGEN network will have important effects on clinical management and it will improve the overall identification and treatment of primary dyslipidemias in Italy
Cancer data quality and harmonization in Europe: the experience of the BENCHISTA Project â international benchmarking of childhood cancer survival by stage
IntroductionVariation in stage at diagnosis of childhood cancers (CC) may explain differences in survival rates observed across geographical regions. The BENCHISTA project aims to understand these differences and to encourage the application of the Toronto Staging Guidelines (TG) by Population-Based Cancer Registries (PBCRs) to the most common solid paediatric cancers.MethodsPBCRs within and outside Europe were invited to participate and identify all cases of Neuroblastoma, Wilms Tumour, Medulloblastoma, Ewing Sarcoma, Rhabdomyosarcoma and Osteosarcoma diagnosed in a consecutive three-year period (2014-2017) and apply TG at diagnosis. Other non-stage prognostic factors, treatment, progression/recurrence, and cause of death information were collected as optional variables. A minimum of three-year follow-up was required. To standardise TG application by PBCRs, on-line workshops led by six tumour-specific clinical experts were held. To understand the role of data availability and quality, a survey focused on data collection/sharing processes and a quality assurance exercise were generated. To support data harmonization and query resolution a dedicated email and a question-and-answers bank were created.Results67 PBCRs from 28 countries participated and provided a maximally de-personalized, patient-level dataset. For 26 PBCRs, data format and ethical approval obtained by the two sponsoring institutions (UCL and INT) was sufficient for data sharing. 41 participating PBCRs required a Data Transfer Agreement (DTA) to comply with data protection regulations. Due to heterogeneity found in legal aspects, 18 months were spent on finalizing the DTA. The data collection survey was answered by 68 respondents from 63 PBCRs; 44% of them confirmed the ability to re-consult a clinician in cases where stage ascertainment was difficult/uncertain. Of the total participating PBCRs, 75% completed the staging quality assurance exercise, with a median correct answer proportion of 92% [range: 70% (rhabdomyosarcoma) to 100% (Wilms tumour)].ConclusionDifferences in interpretation and processes required to harmonize general data protection regulations across countries were encountered causing delays in data transfer. Despite challenges, the BENCHISTA Project has established a large collaboration between PBCRs and clinicians to collect detailed and standardised TG at a population-level enhancing the understanding of the reasons for variation in overall survival rates for CC, stimulate research and improve national/regional child health plans
Tumore a cellule giganti tenosinoviale della mano e del polso: diagnosi precoce e trattamento chirurgico
Quarantadue pazienti affetti da tumore a cellule giganti tenosinoviale e trattati con chirurgia radicale sono stati sottoposti ad un attento follow-up mirato alla valutazione dei risultati e allâanticipazione
diagnostica dellâeventuale ripresa della neoplasia.
Ă importante procedere chirurgicamente con asportazione radicale del tumore poichĂ©, solo se questo Ăš totalmente escisso, il paziente puĂČ
considerarsi libero da malattia ed avere una completa restitutio ad integrum funzionale. La precoce dimostrazione della ripresa della malattia Ăš possibile grazie ad un accurato esame clinico, integrato da esame
ecografico e, in casi selezionati, da risonanza magnetica nucleare
Trattamento chirurgico dei neuromi dâamputazione dolorosi con gel di acido ialuronico. Lavoro preliminare su 6 casi
Il neuroma dâamputazione Ăš la conseguenza di un evento traumatico che ha interrotto la struttura del nervo cui segue un tentativo di riparazione del
tessuto. La lesione determina iposensibilitĂ della regione di innervazione e una sindrome dolorosa.
La risoluzione del quadro clinico Ăš possibile tramite lâasportazione chirurgica del neuroma e lâaffondamento del moncone.
Lâimpiego dellâacido ialuronico (HyaloglideÂź 0,8-1 ml) Ăš basato sulla necessitĂ di proteggere il moncone prossimale dagli stimoli meccanici e termici responsabili dei tipici sintomi del neuroma dâamputazione.
In questo studio abbiamo impiegato lâacido ialuronico in sei casi clinici di neuroma dâamputazione doloroso degli arti superiori ed inferiori. Descriviamo i metodi ed i risultat
- âŠ